These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33666363)

  • 1. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
    Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
    Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.
    Humbert O; Radtke S; Samuelson C; Carrillo RR; Perez AM; Reddy SS; Lux C; Pattabhi S; Schefter LE; Negre O; Lee CM; Bao G; Adair JE; Peterson CW; Rawlings DJ; Scharenberg AM; Kiem HP
    Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
    Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
    J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 Editing of the
    Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
    N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genome Editing System for Therapeutical Targeting of Stem Cells.
    Frati G; Miccio A
    Methods Mol Biol; 2021; 2185():383-398. PubMed ID: 33165862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation for engraftment of CD34
    Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
    Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Edited Stem Cell Transplantation for HIV-Related Gene Modification In Vivo: A Systematic Review.
    Widjaya MA; Ju JC; Lee SD
    Stem Cell Rev Rep; 2022 Jun; 18(5):1743-1755. PubMed ID: 35169967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.
    Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M
    CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
    Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
    Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
    Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
    Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs.
    Crippa S; Conti A; Vavassori V; Ferrari S; Beretta S; Rivis S; Bosotti R; Scala S; Pirroni S; Jofra-Hernandez R; Santi L; Basso-Ricci L; Merelli I; Genovese P; Aiuti A; Naldini L; Di Micco R; Bernardo ME
    Mol Ther; 2023 Jan; 31(1):230-248. PubMed ID: 35982622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells.
    Brault J; Liu T; Liu S; Lawson A; Choi U; Kozhushko N; Bzhilyanskaya V; Pavel-Dinu M; Meis RJ; Eckhaus MA; Burkett SS; Bosticardo M; Kleinstiver BP; Notarangelo LD; Lazzarotto CR; Tsai SQ; Wu X; Dahl GA; Porteus MH; Malech HL; De Ravin SS
    Front Immunol; 2022; 13():1067417. PubMed ID: 36685559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones.
    Smith RH; Chen YC; Seifuddin F; Hupalo D; Alba C; Reger R; Tian X; Araki D; Dalgard CL; Childs RW; Pirooznia M; Larochelle A
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33322084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
    Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
    Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.